Clinical Trials Logo

Clinical Trial Details — Status: Not yet recruiting

Administrative data

NCT number NCT06390566
Other study ID # APHP230610
Secondary ID
Status Not yet recruiting
Phase
First received
Last updated
Start date April 30, 2024
Est. completion date April 30, 2026

Study information

Verified date October 2023
Source Assistance Publique - Hôpitaux de Paris
Contact Edoardo Malfatti, Professor
Phone 0033149814496
Email edoardo.malfatti@aphp.fr
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

Limb girdle muscular dystrophies were originally defined as a postnatal progressive muscle disease, which begins and primarily affects the pelvic and scapular muscles.


Description:

Intro: Limb girdle muscular dystrophies were originally defined as a postnatal progressive muscle disease, which begins and primarily affects the pelvic and scapular muscles. To be considered a form of limb-girdle muscular dystrophy, according to the European Neuromuscular Center, the condition must be described in at least two unrelated families with affected individuals achieving independent walking, must have elevated serum creatine kinase activity, must demonstrate degenerative changes on muscle imagery over the course of the disease, and must exhibit dystrophic changes on muscle histology, ultimately leading to end-stage pathology for the most affected muscles. They are classified into dominant forms (LGMD 1, old nomenclature; LGMD D, new nomenclature) and recessive forms (LGMD 2, old nomenclature; LGMD R new nomenclature). Recessive forms predominate in terms of number of subtypes and individual prevalence, with regional variations due to founder effects in some cases (Murphy et al, 2015). Individually, distinct subtypes of LGMD are relatively rare; however, as a group, the minimum prevalence of LGMD is probably between 2.27 per 100,000 and 10 per 100,000. In Europe and the United States, calpainopathies, also called LGMD R1 or LGMD-2A (OMIM 253600 ), are the most common of the different types of LGMD, accounting for up to 30% of all cases of recessive LGMD. There is currently no cure for the disease, the management of which is still based on rehabilitation therapies and the prevention of other complications. The development of new therapeutic approaches, in particular gene therapies, requires the best possible characterization of the natural history of the disease, in order to identify the patients with the most unfavorable evolutions and to characterize their chronology, and in order to identify the clinical and paraclinical parameters that are most sensitive to change, allowing the effectiveness of new treatments to be better assessed in future randomized trials. However, there are currently no or few recent data from prospective cohorts representative of the population of interest and including detailed phenotyping data such as muscle MRI. Hypothesis/Objective Primary objective : The main objective of this study is to identify and quantify the loss of strength of the muscle groups of the upper (e.g.: raising the arms, lifting a weight, etc.) and lower (e.g.: walking, standing, etc.) limbs over a period of time. of 2 years in 25 patients suffering from LGMD2A already followed at the Reference Center for Neuromuscular Diseases of Mondor Hospital. Secondary objectives: - Define the evaluation criteria (scales, measurements) capable of defining the therapeutic response after the gene therapy clinical trial, - Describe the loss of muscle functions (inability to raise the arms, wheelchair) and muscle weakness of the upper and lower limbs, - Identify and monitor imaging and laboratory analysis parameters which are indicators of the progression of the disease leading to muscle deficit. Method Primary evaluation criteria: Assessment of motor function • Assessment of change from baseline in motor function assessed with the North Star Assessment (NSAD) scale score for Limb Girdle Muscular Dystrophies. Secondary evaluation criteria: Assessment of motor function of the upper and lower limbs - Assessment of motor function of the upper and lower limbs with the Brooke and Vignos scales Assessment of muscle strength - 1) Isometric manual muscular assessment - 2) Quantitative isometric muscle evaluations (Quantitative Muscle Testing (QMT)) - Myotools and manual dynamometer (Hand Held Dynamometry (HHD)) Assessment of motor function of the upper limbs - Assessment of the upper limbs using the PUL (Performance of the Upper Limb) assessment tool, filmed version using 3 cameras Assessment of movement activity Walking Ability Using the FeetMe® Monitor Muscle MRI - Muscle anatomy (volume, fatty infiltration) - Modified Mercuri Score (mMS) to measure fat splitting Laboratory analysis Biobank samples: - Blood sampling for hematology analyzes - Blood sampling for biochemistry analysis (CK) - Blood sampling for coagulation analysis Quality of life questionnaire - Quality of life questionnaire for genetic neuromuscular diseases (gNMD) and ACTIVLIM questionnaire Conclusion The overall objective of the analyzes planned in this study is to characterize disease progression in patients with LGMD2A over a period of up to 24 months. The choice of a study duration of 24 months is linked to the fact that over a shorter period significant changes would not have been observable and a longer duration would have greatly increased the burden and scale of the study at the time. logistical level. It is important to develop detailed natural history data to better understand the driving course of the disease and validate assays as well as clinical outcome measures to define relevant endpoints for future clinical trials.


Recruitment information / eligibility

Status Not yet recruiting
Enrollment 25
Est. completion date April 30, 2026
Est. primary completion date April 30, 2026
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Confirmed diagnosis of autosomal recessive LGMD2A (two pathogenic mutations in the calpain 3 gene) - Ability to participate in the tests and examinations planned by the study (manual muscle tests, motor scales) - Informed and having signed a consent form - Affiliate to a social security scheme in France (beneficiary or entitled person). Exclusion Criteria: - Patient with another disease likely to significantly interfere with the interpretation of the natural history of LGMD2A - Participant in a clinical trial with an investigational product within 3 months preceding inclusion - Patient unable or unwilling to comply with protocol requirements - Patient under guardianship, curatorship or legal protection - Pregnant or breastfeeding woman - Patient deprived of liberty - Adult patient unable to express consent - Refusal to participate

Study Design


Related Conditions & MeSH terms


Intervention

Other:
calpaïnopathies
Identify and quantify the loss of strength of upper and lower limb muscle groups in patients with LGMD2A

Locations

Country Name City State
n/a

Sponsors (1)

Lead Sponsor Collaborator
Assistance Publique - Hôpitaux de Paris

Outcome

Type Measure Description Time frame Safety issue
Primary Evaluation of the loss of strength of muscle groups in patients with LGMD2A identify and quantify the loss of strength of upper and lower limb muscle groups in patients with LGMD2A 2 years
See also
  Status Clinical Trial Phase
Recruiting NCT04001595 - Global FKRP Registry
Recruiting NCT05409079 - Schulze Muscular Dystrophy Ability Clinical Study N/A
Active, not recruiting NCT05906251 - A Gene Transfer Study to Evaluate the Safety, Tolerability and Efficacy of SRP-6004 in Ambulatory Participants With Limb Girdle Muscular Dystrophy, Type 2B/R2 (LGMD2B/R2, Dysferlin [DYSF] Related) Phase 1
Recruiting NCT05230459 - A Study to Evaluate the Safety of AB-1003 (Previously LION-101) in Subjects With Genetic Confirmation of LGMD2I/R9 (Part1) Phase 1/Phase 2
Recruiting NCT03981289 - Defining Clinical Endpoints in Limb Girdle Muscular Dystrophy (LGMD)
Completed NCT02836418 - Study to Evaluate the Long-Term Safety, Tolerability, and Biological Activity of ATYR1940 in Participants With Limb Girdle and Facioscapulohumeral Muscular Dystrophy (FSHD) Phase 1/Phase 2
Active, not recruiting NCT03930628 - Limb-Girdle Muscular Dystrophy Type 2I in Norway
Recruiting NCT05618080 - Trial Readiness and Endpoint Assessment in LGMD R1
Completed NCT01066455 - Cardiac Outcome Measures in Children With Muscular Dystrophy N/A
Active, not recruiting NCT05206617 - 3 Year Follow up on ANO5 Patients
Completed NCT01126697 - Clinical Trial of Coenzyme Q10 and Lisinopril in Muscular Dystrophies Phase 2/Phase 3
Withdrawn NCT02245711 - Cell Therapy in Limb Girdle Muscular Dystrophy Phase 1
Withdrawn NCT02050776 - Stem Cell Therapy in Limb Girdle Muscular Dystrophy Phase 1
Active, not recruiting NCT05876780 - A Gene Transfer Single Dose Study to Evaluate the Safety, Tolerability and Efficacy of SRP-9003 in Non-Ambulatory and Ambulatory Participants With Limb Girdle Muscular Dystrophy, Type 2E/R4 (Beta-Sarcoglycan [β-SG] Deficiency) Phase 1
Recruiting NCT06378203 - Rehabilitation in Muscular Dystrophies From the Hospital Facility to the Home: Pilot Project [RIMUDI] N/A
Completed NCT04202627 - Biomarker Development in LGMD2i
Completed NCT01081080 - Cardiac Magnetic Resonance in Children With Muscular Dystrophy N/A
Recruiting NCT05102799 - MRI-phenotyping of Patients With Pathogenic Anoctamin 5 Variants